Test for statin side effects launched

Some people stop taking statins because of fears over side effects. Credit: iStockphoto/Marcelo Wain

(Medical Xpress) -- A simple diagnostic test developed at Oxford University, and launched today by Massachusetts-based Boston Heart Diagnostics, will identify those at increased risk of rare but serious side effects from taking cholesterol-lowering statin drugs.

Isis Innovation, the University's technology commercialisation company, granted Boston Heart Diagnostics an exclusive US license to the test in 2011. The test is now available for license in non-US territories, including the UK.

Researchers at Oxford University's Clinical Trial Service Unit, led by Professor Rory Collins, identified the genetic biomarker SLCO1B1, which is an effective identifier of patients at increased risk of myopathy – the onset of muscle aches, pains and weakness associated with statin therapy. This condition can be extremely unpleasant and occasionally becomes very serious.

"Lowering cholesterol with statin therapy results in a substantial reduction in heart attacks, stroke and cardiovascular mortality and larger reductions in produce larger benefits," said Professor Collins. "In rare cases, myopathy occurs in association with statin therapy, especially when the statins are given at higher doses and with certain other medications. Knowledge of the SLCO1B1 marker may help to achieve the benefits of statin therapy more safely and effectively."

Boston Heart Diagnostics has now launched the Statin Induced Myopathy (SLCO1B1) Genotype test. The test classifies individuals into high risk or low risk genotypes based on the presence or absence of the SLCO1B1 .

"Of course there are any number of reasons that people ignore their healthcare provider's advice, but statin-induced myopathy can be extremely unpleasant and, for a small percentage, completely debilitating – leading many to forego taking the potentially life-saving drug," said Boston Heart Diagnostics President and CEO Susan Hertzberg.

"We are delighted to assist in bringing this important new test to the US market through an exclusive arrangement with Boston Diagnostics," said Tom Hockaday, Managing Director of Isis Innovation. "The test has the potential to allow physicians worldwide to assist patients to choose the best and safest treatment option for their particular case.'

add to favorites email to friend print save as pdf

Related Stories

Major study finds no evidence that statins cause cancer

Aug 31, 2010

In the largest and most reliable study of its type, the University of Oxford (UK) and the University of Sydney (Australia) have demonstrated that statin therapy is not a cause of increased cancer rates and deaths. The conclusions ...

Common Gene Mutation Linked to Statin Side Effects

Oct 13, 2009

(PhysOrg.com) -- Common genetic mutations may help explain why some people develop side effects that lead to discontinuing the use of cholesterol-lowering statins. Duke University Medical Center researchers who identified ...

Recommended for you

Leeches help save woman's ear after pit bull mauling

19 hours ago

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

New pain relief targets discovered

Apr 17, 2014

Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. BBSRC-funded researchers at King's College London made the discovery when researching ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

PeterD
not rated yet Jun 05, 2012
Only an idiot would take statins since there is no evidence that shows that these drugs help you live longer. they are a complete fraud!